Endothelial injury in vivo is associated with platelet deposition and a localized plateletdependent vasoconstrictive response. To assess the influence of nitroglycerin on platelets and vasoconstriction, quantitative`111n-labeled platelet deposition (no platelets x 106/cm2) of the injured segment and the degree of angiographic vasoconstriction (percent diameter narrowing proximal and distal to the dilated segment) produced during injury by balloon angioplasty of the common carotid arteries were studied in heparinized normal pigs that were sacrificed immediately after the procedure. In deeply injured (injury extending through the internal elastic lamina) compared with mildly injured (deendothelialization only) arteries, there was both greater platelet deposition (63.8 vs. 6.9, p = 0.04) and more vasoconstriction (30% vs. 19 %, p = 0.02). In the presence of deep arterial wall injury, nitroglycerin given intravenously at a dose sufficient to lower mean arterial pressure by 9 2% significantly decreased both platelet deposition (16.2 vs. 63.8, p<0.008) and the vasoconstrictive response (20 vs. 30%, p<0.02) relative to control. However, in the presence of mild arterial wall injury, nitroglycerin decreased vasoconstriction relative to control (10% vs. 19%, p<0.01) without causing a significant decrease in the already low level of platelet deposition (5.6 vs. 6.9, respectively; p=NS), suggesting a direct smooth muscle relaxant effect of nitroglycerin. This is the first reported in vivo effectiveness of nitroglycerin in the reduction of platelet deposition after deep arterial injury. (Circulation 1988;78:712-716) itroglycerin has been used for over a century for the prevention and relief of myocardial ischemia. Its proven clinical efficacy is believed to be related to its vasodilatory effects on the coronary and systemic vascular beds.1-4 However, the exact mechanism by which nitroglycerin produces vasodilatation or relieves vasoconstriction remains to be elucidated. Recent in vitro studies have shown that nitrates can relax vascular smooth muscles through an endothelium-independent mechanism,56 which may explain its remarkable efficacy in relieving vasoconstriction that is often localized to the site of atherosclerosis where the endothelium may be injured or dysfunctional.7 Disruption of the endothelial barrier also leads to localized platelet depositions that may contribute to the vasoconstrictive response by releasing potent vasoconstrictive substances.9-'3 Nitroglycerin inhibits 
mm; during dilatation, the diameter of the inflated balloon within the artery was not more than 10% bigger than the original arterial lumen (measured on plain x-ray films taken during the procedure and compared with predilatation angiograms).
Quantitation of Vasoconstriction
To quantitate the severity of localized vasoconstriction immediately proximal and distal to the dilatation site, angiograms of the common carotid arteries were obtained in all pigs before and after the dilatation procedure; for these two selective intra-arterial injections at the beginning and end of the procedure, 6 ually titrated to produce a 10% fall in mean arterial pressure. This hemodynamic response, which has been shown to be associated with beneficial effects in both humans and experimental animals, 18, 19 required an infusion of 1,151 + 235 ,g/min nitroglycerin in the pigs. Although this rate may be higher than that usually infused in humans (and may reflect a different pharmacokinetic and pharmacodynamic profile in pigs as opposed to humans), doses up to 1,020 gg/min have been infused to achieve clinical benefit in patients.20 Ten pigs randomly assigned to nitroglycerin vehicle (n = 4, 2.4% alcohol, 2.4% propylene glycol) or 5% dextrose in water (n = 6) served as controls. Platelet deposition and vasoconstriction in the vehicle-treated group did not differ from the dextrose in water-treated group.
Tissue Preparation
At the completion of the angioplasty procedure, the animals were given a lethal dose of sodium pentobarbital and perfused antegradely with 2% glutaraldehyde and 1% paraformaldehyde in 0.1 M cacodylate (pH 7.25) at 100 mm Hg for 15 minutes to fix the arteries in situ. The carotid arteries were then removed, cleaned of all adventitia, and prepared for analysis.
The dilated portion of the fixed artery was easily identified because of the in situ fixation that showed the regions of vasoconstriction proximally and distally to the dilated area and from the spot films taken during and after the angioplasty.9 The dilated portion was divided into two equal segments, each about 1.5 cm; segments were also taken from the distal uninvolved artery.
Histopathology
From each arterial segment, two-or three-ring sections were removed and stained with hematoxylin and eosin and Lason's elastin-Van Gieson stain. The histological sections were examined by two investigators to provide consensus evaluation of the presence of medial tears. An intimal tear extending through the internal elastic lamina into the media was defined as deep arterial wall injury; endothelial denudation without a tear through the internal elastic lamina was mild injury.9
Quantitation of Platelet Deposition Autologous platelets were labeled with "'1In (tropolone)3 (300-400 gQCi)21 and injected into the animal 18-24 hours before angioplasty. The quantitative platelet deposition on the arterial segments was calculated from the blood platelet counts, and the "'In activity on the arterial wall (arterial segments counted in a well counter) and in blood, as described.2' The number of platelets per unit area (x 106/cm2) was then obtained by dividing the number of deposited platelets per arterial segment by the arterial wall surface area (area = r x d x e; d is diameter of segment and f is length of arterial segment).
Statistical Analysis
All values are expressed as mean + SEM unless otherwise indicated. Differences between group means were assessed by a two-tailed Student's group t test; p<0.05 was considered significant. Table 1 ). In the presence of mild arterial wall injury, nitroglycerin did not decrease platelet deposition relative to control (5.6 ± 0.9 vs. 6.9 + 0.5) but did significantly decrease the vasoconstriction relative to control (10 + %, n =6 arteries, vs. 19 ± 2%, n = 7 arteries, p = 0.01) ( Table 1) . During therapy with nitroglycerin, the vasoconstrictive response was also significantly greater in the arteries with deep injury compared with mild injury (20 ± 3% vs. 10 ± 1%, respectively, p<0.04) and was associated with greater residual platelet deposition in the deeply injured compared with the mildly injured group (16.2 ± 2.3 vs. 5.6 ± 0.9, respectively; p<0.01) even though the decrease in mean arterial pressure was the same in both groups (9±2%). Discussion This study demonstrates a new and unexpected finding for an old vasodilator drug, namely, that intravenous nitroglycerin can be a potent and effective platelet inhibitor agent in vivo; this supports its inhibition of platelet aggregation in vitro14-16 and its inhibition of whole blood platelet aggregation in vivo at therapeutic doses (titrated to a 10-mm Hg reduction in blood pressure) in humans when measured at the bedside within 60 seconds of sampling (but not after 30 minutes of incubation).22 As expected, it can also decrease vasoconstriction in the presence of deep arterial wall injury. However, the adherence of a single layer of platelets to the exposed subendothelium in the presence of mild injury appears resistant to inhibition by nitroglycerin as we have also observed with other platelet inhibitor therapies.9,23
Nitroglycerin also produced a significant decrease in the vasoconstrictive response associated with arterial wall injury. This is consistent with its potent endothelium-independent vasodilator properties. 6 In this model, we have shown that there is also a platelet-dependent component to this vasoconstrictive response,9 and aspirin, an antiplatelet agent with no known vasodilator properties, can decrease this vasoconstrictive response by decreasing platelet deposition.9 Thus, in addition to its direct vascular-smooth muscle relaxant effect, nitroglycerin probably has a further vasodilating effect mediated by its antiplatelet properties, but in this study we had no way to determine how much of the vasodilation was endothelium-independent and how much was platelet-dependent. We can only infer that a platelet-dependent component was present based on the greater platelet deposition and vasoconstriction after deep compared with mild injury (with and without nitroglycerin) and our previous study with low-dose aspirin. 9 The vasodilator response to nitroglycerin, not related to a decrease in platelet deposition in mild injury probably represents its direct action on vascular smooth muscle causing relaxation, an intrinsic property of nitroglycerin likely related to cyclic guanosine monophosphate (cGMP) generation.56 Thus, at least two mechanisms may contribute to the decrease in vasoconstriction at the site of arterial wall injury in vivo by nitroglycerin: first, a direct smooth muscle relaxant effect independent of the presence of the endothelium and independent of platelets and, second, a decrease in platelet deposition and the platelet-dependent vasoconstriction.
Localized vasoconstriction after endothelial injury in vivo may result from endothelial injury.24 This may reduce endothelium-derived relaxation factor(s),25 and prostacyclin (PGI2) production,26 or may promote platelet deposition and release of platelet-derived vasoconstrictive substances.7-'3 The relative contribution of these components is unknown. Localized vasoconstriction is also influ-enced by the vascular smooth muscle responsiveness because vasoconstriction does not occur in the dilated region where necrosis of smooth muscle cells results but does occur immediately proximal and distal to the dilated region where there is endothelial cell denudation but no necrosis of smooth muscle cells.8 '9 Initial in vivo and in vitro studies showed that nitroglycerin can enhance endothelial prostacyclin synthesis and inhibit platelet thromboxane A2 production, '4-16 In this study, we have shown that nitroglycerin decreased both platelet deposition and localized vasoconstriction; this may explain, at least in part, its beneficial clinical effects. The antiplatelet effect of nitroglycerin in vivo may contribute to its vasodilator effect.
